Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for at least 4 months after the last dose of cemiplimab.
Cemiplimab-Rwlc is a biosimilar to Cemiplimab.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Libtayo (Regeneron); REGN2810 (Regeneron)
- INDICATIONS: Metastatic (or locally advanced) cutaneous squamous cell carcinoma.
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immune checkpoint inhibitor (incl. programmed death receptor-1 (PD-1) inhibitor), Monoclonal antibody, Programmed death-ligand (PD-L1) inhibitor
- HALF-LIFE: 19 days
- FDA APPROVAL DATE: 09/28/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Based on its mechanism of action, cemiplimab cause fetal harm when administered to a pregnant woman. There are no available data on the use of cemiplimab-rwlc in pregnant women.
Please login to view the rest of this drug profile.
Page last updated 04/06/2025
